SpringWorks Therapeutics is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. SpringWorks developed and is commercializing the first FDA-approved medicine for adults with desmoid tumors and the first FDA-approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). SpringWorks is also advancing a portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X, LinkedIn, Facebook, Instagram and YouTube.